Guy Fish, MD, MBA, has extensive health care experience as a physician and a consultant in numerous executive leadership roles which encompass both the for-profit and nonprofit health care sectors. Before joining GLFHC in July 2021, Fish was acting CEO of Nextstage Therapeutics, a Spanish company with exosome technologies. Prior to that, he was CEO of Cellanyx Diagnostics, which uses artificial intelligence to predict which cancers are aggressive and which are not. Before Cellanyx, Fish was a leader with profit and loss responsibilities for 17 years at the health care strategy consulting firm Fletcher Spaght, Inc. His market assessments, due diligence in acquisitions, fundraising, and strategic growth planning for a wide range of medical services and products resulted in substantial value creation over the last ten years. In the nonprofit sector, Fish is Chairman of the Board of Trustees at health care think-tank Altarum Institute which is focused on improving the health of marginalized communities. As treasurer of the Harvard Alumni Association, he spearheaded initiatives to advance social justice and anti-racism. Fish is also a Lay Trustee of the Beth Israel Deaconess Medical Center and has chaired both the Patient Care Committee and the Medical Education Committee.